Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 490

1.

Determinants of survival following HIV-1 seroconversion after the introduction of HAART.

Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Porter K, Walker AS; CASCADE Collaboration.

Lancet. 2003 Oct 18;362(9392):1267-74.

PMID:
14575971
[PubMed - indexed for MEDLINE]
3.

[Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].

Pezzotti P, Dorrucci M, Donisi A, Cusini M, Mazzarello G, De Luca A, Salassa B, Ursitti MA, Giuliani M, Rezza G; l'Italian Seroconversion Study.

Epidemiol Prev. 2003 Nov-Dec;27(6):348-55. Italian.

PMID:
15058363
[PubMed - indexed for MEDLINE]
4.

A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival.

Mocroft A, Madge S, Johnson AM, Lazzarin A, Clumeck N, Goebel FD, Viard JP, Gatell J, Blaxhult A, Lundgren JD.

J Acquir Immune Defic Syndr. 1999 Dec 1;22(4):369-78.

PMID:
10634199
[PubMed - indexed for MEDLINE]
5.

Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category.

Pérez-Hoyos S, del Amo J, Muga R, del Romero J, García de Olalla P, Guerrero R, Hernàndez-Aguado I; GEMES (Spanish Multicenter Study Group of Seroconverters).

AIDS. 2003 Feb 14;17(3):353-9.

PMID:
12556689
[PubMed - indexed for MEDLINE]
6.

Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE.

CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe) Collaboration.

HIV Med. 2000 Oct;1(4):224-31.

PMID:
11737353
[PubMed - indexed for MEDLINE]
7.

Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.

Sánchez JM, Ramos Amador JT, Fernández de Miguel S, González Tomée MI, Rojo Conejo P, Ferrnado Vivas P, Clemente Vivas J, Ruiz Contreras J, Nogales Espert A.

Pediatr Infect Dis J. 2003 Oct;22(10):863-7.

PMID:
14551485
[PubMed - indexed for MEDLINE]
8.

Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.

Jacobson LP, Li R, Phair J, Margolick JB, Rinaldo CR, Detels R, Muñoz A.

Am J Epidemiol. 2002 Apr 15;155(8):760-70.

PMID:
11943695
[PubMed - indexed for MEDLINE]
Free Article
9.

Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.

Kohli R, Lo Y, Howard AA, Buono D, Floris-Moore M, Klein RS, Schoenbaum EE.

Clin Infect Dis. 2005 Sep 15;41(6):864-72. Epub 2005 Aug 16.

PMID:
16107987
[PubMed - indexed for MEDLINE]
Free Article
10.

Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men.

Prins M, Sabin CA, Lee CA, Devereux H, Coutinho RA.

AIDS. 2000 Aug 18;14(12):1829-37.

PMID:
10985321
[PubMed - indexed for MEDLINE]
11.

Geographical variation in disease progression in HIV-1 seroconverted injecting drug users in Europe?

Prins M, Brettle RP, Robertson JR, Hernández Aguado I, Broers B, Carré N, Goldberg DJ, Zangerle R, Coutinho RA, van den Hoek A.

Int J Epidemiol. 1999 Jun;28(3):541-9.

PMID:
10405862
[PubMed - indexed for MEDLINE]
Free Article
12.

Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.

Rodríguez-Arenas MA, Jarrín I, del Amo J, Iribarren JA, Moreno S, Viciana P, Peña A, Sirvent JL, Vidal F, Lacruz J, Gutierrez F, Oteo JA, Asencio R, Castilla J, Hoyos SP; CoRIS-MD.

AIDS Res Hum Retroviruses. 2006 Aug;22(8):715-23.

PMID:
16910826
[PubMed - indexed for MEDLINE]
13.

Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.

Wong KH, Chan KC, Lee SS.

Clin Infect Dis. 2004 Sep 15;39(6):853-60. Epub 2004 Aug 27.

PMID:
15472819
[PubMed - indexed for MEDLINE]
Free Article
15.

Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001.

García de la Hera M, Ferreros I, del Amo J, García de Olalla P, Pérez Hoyos S, Muga R, del Romero J, Guerrero R, Hernández-Aguado I; GEMES.

J Epidemiol Community Health. 2004 Nov;58(11):944-50.

PMID:
15483312
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Determinants of progression to AIDS in HIV-infected individuals: an update from the Italian Seroconversion Study.

Rezza G.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17 Suppl 1:S13-6.

PMID:
9586645
[PubMed - indexed for MEDLINE]
17.

Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.

Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR 3rd; Pediatric AIDS Clinical Trials Group 219/219C Study Team.

Clin Infect Dis. 2008 Feb 15;46(4):507-15. doi: 10.1086/526524.

PMID:
18199042
[PubMed - indexed for MEDLINE]
Free Article
18.

Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.

Detels R, Muñoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, Schrager LK, Phair JP.

JAMA. 1998 Nov 4;280(17):1497-503.

PMID:
9809730
[PubMed - indexed for MEDLINE]
19.

Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.

Tai JH, Udoji MA, Barkanic G, Byrne DW, Rebeiro PF, Byram BR, Kheshti A, Carter JD, Graves CR, Raffanti SP, Sterling TR.

J Infect Dis. 2007 Oct 1;196(7):1044-52. Epub 2007 Aug 29.

PMID:
17763327
[PubMed - indexed for MEDLINE]
Free Article
20.

Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.

Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR.

J Infect Dis. 2004 Sep 15;190(6):1046-54. Epub 2004 Aug 17.

PMID:
15319852
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk